Latest news with #JAKinhibitors
Health Line
7 days ago
- Health
- Health Line
Does Medicare Cover Rinvoq?
Doctors prescribe Rinvoq (upadacitinib) to treat certain inflammatory conditions, such as rheumatoid arthritis (RA) and ulcerative colitis (UC). It's available as an extended-release oral tablet and an oral solution known as Rinvoq LQ. Rinvvoq belongs to the drug class known as Janus kinase (JAK) inhibitors. Generally, Medicare drug plans can cover Rinvoq. But whether they do or not and how much you must pay out of pocket depends on the specific plan. Which Medicare plan covers Rinvoq? You can get Medicare coverage for prescription drugs via a stand-alone Medicare Part D or a Medicare Advantage prescription drug (MAPD) plan. Private insurers manage these plans and set their coverage and costs. According to the manufacturer's website, experts have performed clinical trials involving Rinvoq for more than 11 years and have prescribed it to more than 100,000 people for RA in the United States since 2019. With both types of drug coverage, your plan must cover at least two drugs from commonly prescribed drug categories. This means that Medicare drug plans may cover them. If they don't, they often cover alternative drugs within the same categories with similar effectiveness. You can check whether your specific plan covers Rinvoq by examining the plan's formulary, which lists all the drugs the plan covers. How much is a 30-day supply of Rinvoq? Without insurance, Rinvoq is a pricey drug. As of 2025, the list cost of a 30-day supply of the drug is $6,752.77. If your Medicare drug plan covers the drug, how much you pay out of pocket depends on the drug's tier within the plan's formulary. Generally, generic drugs tend to be in lower tiers, costing less. However, currently there's no generic version of Rinvoq. That said, under a Medicare drug plan, you may never pay more than $2,000 out of pocket on prescription drugs per year in 2025. Once you reach this amount, your plan may cover the rest of your annual cost in full. This limit changes from year to year. In 2026, it may rise to $2,100. In addition, no Medicare drug plan deductible can be higher than $590 in 2025.
Yahoo
24-06-2025
- Business
- Yahoo
Market Accelerates Amid Rising Disease Prevalence, Kinase Innovation, and Demand for Safer Treatments
The global kinase inhibitors in autoimmune diseases market is experiencing significant growth, driven by rising autoimmune disease prevalence and advancements in biotechnology, specifically in targeted therapies like JAK inhibitors. These innovations provide a precise approach to treatment, addressing the root causes of immune dysfunction and benefiting from expedited regulatory approvals. While challenges such as high costs and competition persist, heavy investments in research and clinical trials suggest sustained market growth. North America is set to lead, backed by robust healthcare infrastructure and regulatory benefits. Major players like Pfizer and Sun Pharmaceuticals are enhancing product offerings, underscoring the competitive landscape. Dublin, June 24, 2025 (GLOBE NEWSWIRE) -- The "Kinase Inhibitors in Autoimmune Diseases Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to offering. The global kinase inhibitors in autoimmune diseases market is currently in the growth stage of its lifecycle. With the increasing prevalence of autoimmune diseases and advancements in biotechnology, the demand for targeted therapies such as JAK inhibitors has been rising. Increasing demand for kinase inhibitors in autoimmune diseases therapies is anticipated to support the growth of the global kinase inhibitors in autoimmune diseases market during the forecast period 2025-2035. The global kinase inhibitors in autoimmune diseases market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers. These therapies offer a more specific approach to treatment, addressing the underlying causes of immune system dysfunction, which is a key driver for market expansion. The market is also benefitting from regulatory support and faster drug approvals, allowing new treatments to reach the market more quickly. However, challenges like high treatment costs, side effects, and competition from established therapies still are investing heavily in research and clinical trials to expand their drug pipelines and enhance treatment options, signaling continued market growth. As the market matures, it is expected to face increasing competition and pricing pressures, but the demand for more targeted and personalized treatments is likely to sustain its upward trajectory. North America is expected to dominate the global kinase inhibitors in autoimmune diseases market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from regulatory advantages and a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global kinase inhibitors in autoimmune diseases market. How Can This Report Add Value to an Organization?Product/Innovation Strategy: Product launches and innovations in the global kinase inhibitors in autoimmune diseases market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Pfizer, and Sun Pharmaceuticals, have been involved in the development of therapies for kinase inhibitors in autoimmune Strategy: Enterprises led by market leaders in the global kinase inhibitors in autoimmune diseases market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the Developments Launches: In March 2025, Pfizer Korea launched Litfulo (ritlecitinib tosylate), a new Janus kinase (JAK) inhibitor, for the treatment of severe alopecia areata in adolescents and adults, thereby expanding treatment options for patients aged 12 and older in Korea. Regulatory Activities: In July 2024, The U.S. FDA approved Sun Pharmaceutical Industries Ltd.'s Leqselvi (deuruxolitinib), a JAK1 and JAK2 inhibitor, for the treatment of adults with severe alopecia areata, a chronic autoimmune disease. Demand - Drivers and Limitations The following are the drivers for the global kinase inhibitors in autoimmune diseases market: Rising Prevalence of Autoimmune Diseases Advancements in Kinase Inhibition Technology Growing Demand for Non-Immunosuppressive Therapies The global kinase inhibitors in autoimmune diseases market is expected to face some limitations, too, due to the following challenges: High Treatment Costs Limited Indication Scope Key Market Players and Competition Synopsis Pfizer Eli Lilly and Company Reistone Biopharma Incyte Corporation Bristol Myers Squibb Galapagos NV Aclaris Therapeutics Kadmon Pharmaceuticals Sanofi Ono Pharmaceutical Co. Ltd Key Topics Covered: Executive Summary1. Global Kinase Inhibitors in Autoimmune Diseases Market: Industry Outlook1.1 Market Overview and Ecosystem1.2 Market Trends1.3 Epidemiological Analysis of Autoimmune Diseases1.3.1 By Region1.4 Clinical Trials1.4.1 By Phase1.4.2 By Sponsor Type1.5 Regulatory Landscape / Compliance1.5.1 Legal Requirement and Framework in the U.S.1.5.2 Legal Requirement and Framework in the E.U.1.5.3 Legal Requirement and Framework in Asia-Pacific1.6 Market Dynamics1.6.1 Market Drivers1.6.2 Market Restraints1.6.3 Market Opportunities2. Global Kinase Inhibitors in Autoimmune Diseases Market, By Region, $Million, 2023-20352.1 North America2.1.1 Market Dynamics2.1.2 Market Sizing and Forecast2.1.2.1 North America Kinase Inhibitors in Autoimmune Diseases Market (by Country)2.1.2.1.1 U.S.2.1.2.1.2 Canada2.2 Europe2.2.1 Market Dynamics2.2.2 Market Sizing and Forecast2.2.2.1 Europe Kinase Inhibitors in Autoimmune Diseases Market (by Country)2.2.2.1.1 U.K.2.2.2.1.2 Germany2.2.2.1.3 France2.2.2.1.4 Italy2.2.2.1.5 Spain2.2.2.1.6 Rest-of-Europe2.3 Asia-Pacific2.3.1 Market Dynamics2.3.2 Market Sizing and Forecast2.3.2.1 Asia-Pacific Kinase Inhibitors in Autoimmune Diseases Market (by Country)2.3.2.1.1 Japan2.3.2.1.2 China2.3.2.1.3 India2.3.2.1.4 Rest-of-Asia-Pacific2.4 Rest-of-the-World2.4.1 Market Dynamics2.4.2 Market Size and Forecast3. Global Kinase Inhibitors in Autoimmune Diseases Market - Competitive Benchmarking and Company Profiles3.1 Competitive Landscape3.1.1 Key Strategies and Developments by Company3.1.1.1 Funding Activities3.1.1.2 Mergers and Acquisitions3.1.1.3 Regulatory Approvals3.1.1.4 Partnerships, Collaborations and Business Expansions3.1.2 Key Developments Analysis3.2 Company Profiles3.2.1 Company Overview3.2.2 Product Portfolio3.2.3 Target Customers/End Users3.2.4 Analyst View4. Research Methodology For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
30-05-2025
- General
- Medscape
Pediatricians: Stop Atopic Dermatitis With ‘Proactive' Rx
Pediatricians should consider treating children with atopic dermatitis (AD) 'proactively,' according to a new clinical report from the American Academy of Pediatrics (AAP). The AAP defines proactive care as an 'evidence-based' approach based on 'intermittent use of anti-inflammatory agents (eg, topical corticosteroids or tacrolimus twice weekly) on previously affected skin to prevent flares' of AD. The group also recommends newer agents like the Janus kinase (JAK) inhibitors, which may have fewer side effects than long-term steroid use and are more effective than older drugs. The report comes as patients experience long waits for referrals to pediatric dermatologists, said Jennifer Schoch, MD, a professor of dermatology at the University of Florida in Gainesville, Florida, who helped write the document. The recommendations may help primary care clinicians more confidently identify and treat mild to moderate cases of AD, she said. 'Pediatricians play a critical role in initiating topical treatments, educating families, and supporting quality of life,' Schoch said. 'With a proactive approach to topical therapies and an understanding that atopic dermatitis is a chronic condition requiring an ongoing management plan, most cases can be effectively handled in primary care.' JAK inhibitors may be particularly beneficial for treating sensitive areas of the body, supporting patients who have not responded to traditional therapies, and aiding in long-term treatment. Topical JAK 'treatments offer targeted anti-inflammatory effects, which adds to our toolbox, particularly to mitigate concerns about risks of long-term steroid use,' Schoch said. The AAP also now recommends applying topical corticosteroids or topical calcineurin inhibitors proactively to prevent flares. In recent research, patients who were preventively treated with topical steroids experienced a reduction in disease severity and an improved quality of life. The proactive use of nonsteroid topical agents produced similar results. Soft Skills to Build Moisturization and avoidance of triggers like harsh detergents and low humidity continue to be mainstays of maintenance care. Patients should be moisturized using a fragrance-free, thick cream after bathing and handwashing. The AAP advises daily, short baths in lukewarm water and the use of wet wraps and bleach baths. The report emphasized the psychosocial burden of AD in children. AD is associated with mental health issues like stress, depression, and insomnia in children. The recurring, ongoing nature of the disease can place a heavy emotional and economic burden on the entire family, Schoch said. 'Atopic dermatitis can significantly disrupt sleep due to relentless itching, leading to daytime fatigue, irritability, and behavioral challenges in children,' Schoch said. 'The disease may affect school performance, peer relationships, and self-esteem, while caregivers report high levels of stress, anxiety, and even depression.' The new report recommends cognitive-behavioral therapy for patients with mental health concerns and progressive muscle relaxation, sleep hygiene management, and melatonin to reduce insomnia. The use of written action plans may help families follow through with treatment strategies and are 'excellent tool for primary care providers to help explain to patients the stepwise approach of the disease,' said Daniela Russi, MD, a pediatric dermatologist at Phoenix Children's in Phoenix, who was not involved with the report. These plans help 'pediatricians evaluate all aspects of the treatment…in addition to providing proactive ways to prevent flare-ups.' 'This guideline is helpful in showing pediatricians that they are capable of treating mild to moderate atopic dermatitis patients,' Russi said. 'Most of the patients we see in the clinic come without any knowledge of basic skin care, frequency of baths, and use of the correct moisturizers, especially bleach baths and wet wraps.' Schoch reported financial relationships with Janssen Biotech and Exactech. Russi reported having no disclosures. No external funding for the clinical report was used.
Daily Mail
28-05-2025
- General
- Daily Mail
Doctors sound alarm over anti-inflammatory drugs taken by millions that leave you open to deadly viral infections
Drugs were designed to banish discomfort and disease. But a new study has revealed that a class of common anti-inflammatory drugs may actually make people sicker. Researchers from the Norwegian University of Science and Technology (NTNU) discovered that a class of medications called Janus kinase (JAK) inhibitors can make the body vulnerable to viral infections. The medications work by blocking immune system proteins in the body that often lead to inflammation and pain. They are used to treat of a variety medical conditions suffered by millions globally, including rheumatoid arthritis, eczema, alopecia, and certain bone cancers. They are relatively new drugs, and the first JAK inhibitor, sold under the brand name Jakafi for cancer treatment, was only just approved by the FDA in 2011. However, there is now evidence suggesting these drugs - which are typically taken as pills - could help the flu, Covid-19 and other viruses infiltrate the body's immune system, potentially leading to severe infection. The scientists say this is because the drugs 'suppress an important immune signaling pathway that helps protect healthy cells from viral attacks.' The scientists found drugs in the class, such as baricitinib, which is sold under the brand name Olumiant for the treatment of alopecia - slow down the genes that respond to viruses. 'These genes play a crucial role in the body's response to viral infections,' said Aleksandr Ianevski, an NTNU researcher and co-author of the new paper. By stopping or slowing down this pathway, JAK inhibitors remove the body's 'antiviral shield'. This allows viruses to more easily gain a foothold in the body and spread. The researchers used advanced techniques in a lab to look at how JAK inhibitors impact organs and how viruses attack the body once they have been exposed. They examined cells from the lungs, eyes and brain, as well as laboratory-created mini-organs. Off the back of their findings Erlend Ravlo, a PhD research fellow at NTNU, said: 'Although JAK inhibitors are effective in the treatment of inflammation, this shows that they can pose a hidden risk for patients who have latent or active viral infections.' The findings suggest healthcare professionals should be cautious when prescribing JAK inhibitors, especially during viral outbreaks. Common side effects of the medications include headaches, nausea, fatigue, diarrhea, acne, and elevated cholesterol. Meanwhile, rarer but more serious side effects include severe infections like pneumonia or shingles, damage to the stomach or intestines, and changes in blood cell counts. While the immunosuppressive effects of the drugs could be harmful, the researchers point out that it could be useful in controlled environments, such as in the development of vaccines or screening of antiviral drugs. 'We recommend further studies to better understand how the drugs can be used optimally, especially during virus outbreaks or pandemics,' says Ianevski. The researchers hope to increase awareness among doctors and researchers about the effects of these drugs to prevent patients from developing new illnesses. This is especially important for vulnerable patients, such as the elderly or individuals with chronic illnesses or disabilities. The findings were published in the medical journal, NAR Molecular Medicine.
CTV News
27-05-2025
- Health
- CTV News
Common anti-inflammatory drugs may leave body open to viral attacks, study suggests
A new study says some anti-inflammatory drugs could allow viruses to spread more easily. (Credit: Pexels) Some medications used to treat autoimmune diseases may also make viral infections worse, new research suggests. A study from the Norwegian University of Science and Technology (NTNU) found that Janus kinase (JAK) inhibitors — a class of anti-inflammatory drugs — can suppress a key part of the immune response, potentially allowing viruses like influenza and COVID-19 to replicate and spread more easily. JAK inhibitors are used globally for conditions like rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and atopic dermatitis. The researchers say these drugs block an important immune response known as type I interferon (IFN) signalling, which helps infected cells sound the alarm to neighbouring cells, slowing viral spread and giving the body time to mount a broader defence. In a video interview with on Monday, NTNU researcher and study co-author Denis Kaynov compared the body's layered immune response to a race with hurdles. 'These inhibitors remove the first line of hurdles — our innate immune defences — allowing viruses to run faster,' he said. 'Without that early delay, the adaptive immune system doesn't have time to respond properly, which increases the risk that the virus spreads rapidly from cell to cell and organ to organ.' The researchers used a range of human cell types, including lung, eye and brain cells. Kaynov says the team later moved to organoids — simplified lab-grown mini-organs — to mimic the behaviour of full organs more accurately. While JAK inhibitors are effective in controlling chronic inflammatory conditions, Kaynov says they may leave patients vulnerable if they become infected with a virus. 'If you're on this kind of medication and get an infection like the flu, the virus could spread much more easily in the body,' he said. 'It's important to consult your physician if you suspect an infection while taking these drugs.' Although the research remains in early stages, one infectious diseases specialist says the findings are worth noting. 'This is very, very early on in the pipeline,' Isaac Bogoch said in an interview with last week. 'It's pre-clinical research, which is extremely important and needs to be done, but also just the first step.' Bogoch says the broader risks of JAK inhibitors are already well known. 'They're not like taking acetaminophen,' he said. 'There's a well-established link to higher susceptibility to infections — especially bacterial ones — so it's not entirely surprising that viral vulnerability is also being investigated.' Bogoch emphasized that while the research doesn't call for immediate clinical changes, it does raise useful questions about drug safety, especially for older adults or patients with multiple health conditions. Despite the concerns, the NTNU team sees potential upsides. In highly controlled lab environments, the same drug effects that make the body more vulnerable could be used to researchers' advantage — for example, to help manufacture viral materials for vaccines or cancer therapy. Kaynov says clinical trials aren't on the horizon — 'it would potentially kill a lot of people,' he noted — but the lab results could influence how doctors advise patients during active outbreaks. If someone becomes sick while taking JAK inhibitors, Kaynov says they should contact a doctor to assess whether to pause the medication or consider alternatives. 'It really depends on the virus,' he said. 'Some kill in hours or days. Others linger. But the timing of the immune response is critical either way.'
